Fosamax Osteonecrosis of the Jaw Attorney: Statute of Limitations for Fosamax in Ohio

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Awareness

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy context emphasizes broad awareness of therapeutic benefits and risks, often focusing on common side effects and patient education. Within this framework, medications such as bisphosphonates—widely prescribed for bone density management—have been discussed in terms of their intended benefits and general safety profiles. However, as scientific inquiry deepens, attention has increasingly turned to specific, rare adverse events that may arise from long-term pharmaceutical exposure. One such concern involves the potential link between bisphosphonate use and osteonecrosis of the jaw, a condition that has prompted legal and medical scrutiny. This shift in focus moves the discussion from a general health perspective toward a more targeted examination of occupational and patient-specific risk factors. In particular, individuals who have been prescribed these medications over extended periods may face unique exposure considerations, especially when combined with dental procedures or other local factors. The transition from broad health education to a focused concern about medication-related jaw complications underscores the need for careful monitoring and informed decision-making in both clinical and legal contexts.

Understanding Fosamax and Its Approved Uses

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a known adverse effect associated with bisphosphonate therapy, including Fosamax. ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Clinical Presentation and Medical Risks of ONJ

The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The incidence of ONJ is rare. In a study examining bisphosphonate prescription patterns, the incidence of atypical femoral fracture or osteonecrosis of the jaw was uncommon and rare, respectively (https://pubmed.ncbi.nlm.nih.gov/42046648/). Fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years, after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648/). From a medical risk perspective, patients who have taken Fosamax and developed ONJ may face significant clinical challenges. ONJ presents as exposed necrotic bone in the maxillofacial region, often with pain, swelling, and infection. Diagnosis typically involves clinical examination and imaging. The mechanistic pathways linking bisphosphonates to ONJ are thought to involve suppression of bone turnover, anti-angiogenic effects, and impaired mucosal healing, though the exact pathophysiology remains under investigation.

Statute of Limitations for Fosamax Claims in Ohio

For patients in Ohio considering legal action regarding Fosamax and ONJ, the statute of limitations is a critical factor. Ohio law generally requires that a product liability claim be filed within two years from the date the injury was discovered or should have been discovered with reasonable diligence. This timeline can be complex in ONJ cases because the harm may not be immediately apparent after exposure. The time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), and the risk of ONJ may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Therefore, the discovery date may be when a dentist or physician diagnoses ONJ, not when the patient first took Fosamax. Adequacy of warnings is another key consideration. The Fosamax label includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also lists known risk factors and advises that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, patients and healthcare providers may not have been fully aware of this risk, especially in earlier years of Fosamax use.

Legal Considerations and Attorney Guidance

Attorney-related considerations for affected patients include evaluating whether the manufacturer provided sufficient warnings to prescribers and patients, and whether the patient's specific risk factors were adequately communicated. Patients who have developed ONJ after taking Fosamax should consult with a healthcare provider for diagnosis and management, and with a legal professional to understand their rights under Ohio's statute of limitations. The timeline between exposure and documented harm can be prolonged, and early legal consultation is advisable to preserve the ability to file a claim.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in Ohio?

Ohio law generally requires that a product liability claim be filed within two years from the date the injury was discovered or should have been discovered with reasonable diligence. For ONJ, the discovery date is typically when a dentist or physician diagnoses the condition, not when the patient first took Fosamax.

What are the known risk factors for developing ONJ from Fosamax?

Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long does it take for ONJ symptoms to appear after starting Fosamax?

The time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.